Nothing Special   »   [go: up one dir, main page]

AU2003273856A1 - Vr1 antagonists for the treatment of urological disorders - Google Patents

Vr1 antagonists for the treatment of urological disorders

Info

Publication number
AU2003273856A1
AU2003273856A1 AU2003273856A AU2003273856A AU2003273856A1 AU 2003273856 A1 AU2003273856 A1 AU 2003273856A1 AU 2003273856 A AU2003273856 A AU 2003273856A AU 2003273856 A AU2003273856 A AU 2003273856A AU 2003273856 A1 AU2003273856 A1 AU 2003273856A1
Authority
AU
Australia
Prior art keywords
antagonists
treatment
urological disorders
urological
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003273856A
Other versions
AU2003273856A8 (en
Inventor
Masahiro Shiroo
Masomi Tajimi
Yasuhiro Tsukimi
Noriyuki Yamamoto
Takeshi Yura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003273856A1 publication Critical patent/AU2003273856A1/en
Publication of AU2003273856A8 publication Critical patent/AU2003273856A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003273856A 2002-09-24 2003-09-11 Vr1 antagonists for the treatment of urological disorders Abandoned AU2003273856A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02021367 2002-09-24
EP02021367.4 2002-09-24
PCT/EP2003/010111 WO2004028440A2 (en) 2002-09-24 2003-09-11 Vr1 antagonists for the treatment of urological disorders

Publications (2)

Publication Number Publication Date
AU2003273856A1 true AU2003273856A1 (en) 2004-04-19
AU2003273856A8 AU2003273856A8 (en) 2004-04-19

Family

ID=32039089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003273856A Abandoned AU2003273856A1 (en) 2002-09-24 2003-09-11 Vr1 antagonists for the treatment of urological disorders

Country Status (2)

Country Link
AU (1) AU2003273856A1 (en)
WO (1) WO2004028440A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055004A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
WO2005007648A2 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2005035471A1 (en) 2003-10-14 2005-04-21 Ajinomoto Co., Inc. Ether derivative
AU2007288203B2 (en) 2006-08-23 2013-01-17 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US8128591B2 (en) 2008-11-10 2012-03-06 Warsaw Orthopedic, Inc. Multiple component mixing and delivery system
DE102022104759A1 (en) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-crystal screening method, in particular for the production of co-crystals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630515B2 (en) * 1997-08-28 2003-10-07 Afferon Corporation Urinary incontinence therapy
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
MXPA03000458A (en) * 2000-07-20 2004-06-02 Neurogen Corp Capsaicin receptor ligands.
DE60133743T2 (en) * 2000-08-21 2009-07-02 Pacific Corp. NEW THIOUREA DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB0105895D0 (en) * 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
AU2002325381A1 (en) * 2001-07-31 2003-02-24 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
JP2003192587A (en) * 2001-12-26 2003-07-09 Bayer Ag Urea derivative
PL210288B1 (en) * 2002-05-08 2011-12-30 Bayer Healthcare Ag Hydroxy tetrahydro-naphthalenylurea derivatives

Also Published As

Publication number Publication date
WO2004028440A3 (en) 2004-07-15
WO2004028440A2 (en) 2004-04-08
AU2003273856A8 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
SI1474416T1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
IL173909A0 (en) Use of modified cyclosporins for the treatment of hcv disorders
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
SI1530466T1 (en) Use of Nintedanib for the treatment of lung fibrosis
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003291719A1 (en) Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003298911A1 (en) Cyclosporins for the treatment of autoimmune diseases
AU2003293099A1 (en) Treatment of dna damage related disorders
AU2003254146A1 (en) Methods for the treatment of parkinson&#39;s disease
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003273856A1 (en) Vr1 antagonists for the treatment of urological disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2003259074A1 (en) Gal3 antagonists for the treatment of neuropathic pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase